| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbadc41aa91592752369d88100f96411 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
| filingDate |
1987-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7f3d6f844f6f06e6936d3b3f095f79c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3db3e4520da9f17e00d02e38fc5d1fa9 |
| publicationDate |
1997-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0755683-A1 |
| titleOfInvention |
Immunotherapy of tumor with monoclonal antibody against the 17-1A antigen |
| abstract |
A murine monoclonal antibody which specifically binds to an epitope of 17-1A antigen (or of a mixture of at least two of such antibodies)is used for the manufacture of a medicament for treating gastrointestinal tumor (e.g. gastrointestinal adenocarcinoma, colorectal or pancreatic carcinoma) by the parenteral administration (e.g. by intravenous infusion) of multiple doses of at least 100 milligrams or more per dose for a total dose of 0.1-5 grams (e.g. 1-5 grams) of antibody. Novel murine monoclonal antibodies are also described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8158128-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9959628-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-745749-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8808695-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6461824-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9959628-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8343930-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7964371-B2 |
| priorityDate |
1986-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |